Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | RAB9A | P51151 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.66 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030427 | 0.90 | NPC1 (0.63) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL3029719 | 0.88 | HDAC8 (0.62) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL12218426 | 0.88 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL15599961 | 0.84 | MEN1 (0.78) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL3675463 | 0.84 | KCNK3 (0.84) | NPC1RAB9AMEN1KMT2AKCNK3 | |
| SCHEMBL2467402 | 0.84 | PLAU (0.78) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL29068810 | 0.83 | DEGS1 (0.72) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL3794687 | 0.82 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2AKCNK3 | |
| SCHEMBL4255341 | 0.82 | NPC1 (0.81) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL15786695 | 0.82 | NPC1 (0.69) | NPC1RAB9AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110642741-A | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2020-01-03 | — | — | CN | claimed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | claimed |
| EP-2928459-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Baruch S. Blumberg Institute (US) | 2015-10-14 | — | — | EP | claimed |
| CN-104918612-A | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INST HEPATITIS & VIRUS RES | 2015-09-16 | — | — | CN | claimed |
| WO-2014089296-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2014-06-12 | — | — | WO | claimed |
| CN-110642741-A | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2020-01-03 | — | — | CN | disclosed |
| CN-104918612-B | Functionalized benzamide derivatives as antiviral agents against HBV infection | 巴鲁克斯布隆伯格研究所 | 2019-10-25 | — | — | CN | disclosed |
| US-20190092720-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092720-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2019-03-28 | — | — | US | disclosed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | BARUCH S BLUMBERG INST (US) | 2015-10-29 | — | — | US | disclosed |
| CN-104918612-A | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INST HEPATITIS & VIRUS RES | 2015-09-16 | — | — | CN | disclosed |
| WO-2014089296-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089296-A2 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2014-06-12 | — | — | WO | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-4307167-A | REUSABLE PHOTOCONDUCTOR CONTAINING A CHARGE TRANSPORT LAYER AND A CHARGE GENERATION LAYER | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | NPC1 6/4885RAB9A 2138/4885MEN1 4471/4885 |
| US-20190092720-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB2, PHB1 | NPC1 539/4885RAB9A 3534/4885MEN1 4832/4885 |
| US-20150307443-A1 | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, PHB2, PHB1 | NPC1 535/4885RAB9A 3729/4885MEN1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.